skip to the main content area of this page

List of Announcements

  • VIENNA, Austria – October 2017: The 2017 Global Synthetic Drugs Assessment provides an analysis of the global synthetic drugs market in two parts. The first part consists of regional overviews that highlight context-specific dynamics relating to the demand and supply of Amphetamine-Type Stimulants (ATS) and New Psychoactive Substances (NPS) in Africa, Central and Southwest Asia, East and South-East Asia and Oceania, Europe, the Near and Middle East, North and Central America, and South Central America. The second part of this report presents a global thematic analysis of the key trends and emerging developments of the synthetic drugs market.

    For more information, please see:

    UNODC report - “2017 Global Synthetic Drugs Assessment”
    https://www.unodc.org/documents/scientific/Global_Drugs_Assessment_2017.pdf

     

  • GEORGIA, United States – 2017: In June 2017, the Georgia Poison Center detected and triggered a comprehensive response to overdose events involving the new fentanyl analogue cyclopropyl fentanyl. In response to a hospital report of patients with alarming respiratory and central nervous system symptoms, the Georgia Poison Center reviewed poison cases, called hospitals and spoke to Government experts, finding out that there had been other reports of similar cases within the State. Georgia Poison Center then notified the Georgia Department of Public Heath (GDPH), the Georgia Bureau of Investigations (GBI) crime laboratory, the Department of Justice, the Attorney General’s office, the Drug Enforcement Agency (DEA), and other state and local officials to inform them of this new threat.

    As criminal investigations and laboratory tests were underway, the State Health Commissioner’s office disseminated an alert to every hospital in Georgia. Laboratory analysis of the tablets used in these drug overdose cases in Georgia revealed that they contained two fentanyl analogues: U-47700 and cyclopropyl fentanyl.

    For more information, please see:

    Article on the “June 2017 Deadly Novel Synthetic Opioid Exposure Outbreak in Georgia – A Case Study in the Crucial Surveillance Role of Regional Poison Control Centers”
    http://www.georgiapoisoncenter.org/wp-content/uploads/2017/06/June-2017-Deadly-Novel-Synthetic-Opioid-Exposure-Outbreak-in-Georgia_FIN....pdf

    Statement of the United States Department of Public Health on “Opioid overdose in Georgia”
    https://www.gafp.org/opiod-overdose-georgia/

     

     

  • VIENNA, Austria – September 2017: The Global SMART Update (Volume 18, September 2017) “Non-medical use of benzodiazepines: a growing threat to public health?” focusses on the concomitant use of benzodiazepines and opioids which has been linked to a number of deaths that occurred in the recent opioid crisis. While both, opioids and benzodiazepines, are widely used to treat various medical conditions, their concomitant, non-medical use poses severe health risks. This situation has been further exacerbated by the ready availability of counterfeited benzodiazepines and the increasing emergence of “designer benzodiazepines”, a common street name for new psychoactive substances (NPS) belonging to the benzodiazepine class.